User:Mr. Ibrahem/Telmisartan
Clinical data | |
---|---|
Pronunciation | /tɛlmɪˈsɑːrtən/ |
Trade names | Micardis, Actavis, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601249 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Angiotensin II receptor antagonist |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 42–100% |
Protein binding | >99.5% |
Metabolism | Minimal hepatic (glucuronidation) |
Elimination half-life | 24 hours |
Excretion | Faecal 97% |
Identifiers | |
| |
Chemical and physical data | |
Formula | C33H30N4O2 |
Molar mass | 514.629 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Telmisartan, sold under the trade name Micardis among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease.[2] It is a reasonable initial treatment for high blood pressure.[2] It is taken by mouth.[2] Versions are available as the combination telmisartan/hydrochlorothiazide and telmisartan/amlodipine.[2]
Common side effects include upper respiratory tract infections, diarrhea, and back pain.[2] Serious side effects may include kidney problems, low blood pressure, and angioedema.[2] Use in pregnancy may harm the baby and use when breastfeeding is not recommended.[3] It is an angiotensin II receptor antagonist and works by blocking the effects of angiotensin II.[2]
Telmisartan was patented in 1991 and came into medical use in 1999.[4] It is available as a generic medication.[5] A month supply in the United Kingdom costs the NHS less than £2 as of 2019.[5] In the United States the wholesale cost of this amount is about US$10.[6] In 2017, it was the 249th most commonly prescribed medication in the United States, with more than one million prescriptions.[7][8]
References[edit]
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 7 September 2020.
- ^ a b c d e f g "Telmisartan Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ "Telmisartan Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 471. ISBN 9783527607495.
{{cite book}}
: Unknown parameter|name-list-format=
ignored (|name-list-style=
suggested) (help) - ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 178. ISBN 9780857113382.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Telmisartan - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.